When a cheaper GLP-1 actually arrives: the patent timeline, in plain English

News coverage often frames lower-cost GLP-1s as a story about compounding pharmacies, but the real timeline runs through patent law and a handful of older statutes that shape drug pricing and access. Understanding those statutes tells you more about when a cheaper GLP-1 might reach you than any compounding headline. For someone paying cash today, that distinction changes what to watch for, and what to do while waiting.

Before any generic or biosimilar pathway could exist, the FDA needed a system for approving the original drug in the first place, and that system dates back to the Federal Food, Drug, and Cosmetic Act of 1938. That law built the premarket review process the FDA still uses today, requiring a drug to prove its safety before it can reach a pharmacy shelf. Later laws, including the ones that created the generic and biosimilar pathways, all sit on top of this foundation. Without the review system the FDCA established, there would be no approved brand drug to copy, and no equivalence standard for a generic maker to meet. That is why the patent clock described in this series only makes sense once you understand the review system it depends on.

Getting a lower-cost GLP-1 will still mean picking up the phone to your doctor's office, a requirement that traces back to the Durham-Humphrey Amendment of 1951. That amendment made GLP-1 drugs, along with many others, available only by prescription, which means a pharmacist cannot dispense one without a doctor's order. This matters for the cost conversation because price is only one part of the picture. Even after a lower-cost version arrives once patents lapse, a patient will still need a prescription to get it, which keeps a physician involved in the decision. That requirement predates GLP-1s by decades, but it applies to every version of these drugs, brand or generic, once available.

For patients on Medicaid, a lower price does not have to wait on any patent expiring, thanks to a rebate system set up by the Omnibus Budget Reconciliation Act of 1990. That law created the Medicaid Drug Rebate Program, in which manufacturers agree to rebates in exchange for having their drugs covered under Medicaid. For patients enrolled in that program, this rebate arrangement can lower the cost of a GLP-1 today, regardless of whether the drug's patents have expired. It runs on a coverage-for-rebate bargain between the government and the manufacturer, not on generic competition. That makes it worth checking, for eligible patients, even while the underlying patent fight is still unresolved.

Some patients may already be paying less for a GLP-1 without realizing why, if they happen to receive care at a clinic that qualifies for 340B pricing, a program created by the Veterans Health Care Act of 1992. That law lets certain qualifying clinics and hospitals buy outpatient drugs at reduced prices, and some GLP-1 patients can access those lower costs depending on where they receive care. Like the Medicaid rebate program, this discount is set by statute and does not depend on whether a drug's patent has lapsed. It offers no promise for patients outside the 340B system, but for those who qualify, it is worth asking a clinic directly whether they participate.

The compounding pharmacies making headlines did not appear outside the law. The FDA Safety and Innovation Act of 2012 created the drug shortage list. Compounding law, in sections 503A and 503B of the food and drug law, added in 1997 and 2013, lets pharmacies and outsourcing facilities make copies of drugs on that list. That is what allowed compounded GLP-1s to spread from 2022. The FDA found the tirzepatide shortage over in late 2024 and the semaglutide shortage over in February 2025, and the last grace periods ended in 2025, so that option has closed. It was a separate, temporary arrangement from the patent-based path described earlier, and it did not offer the lasting price relief that generic competition can bring.

None of these five laws will hand a patient a lower price on their own, but together they describe the full set of options available while waiting for GLP-1 patents to expire. For patients enrolled in Medicaid or receiving care at a 340B clinic, it may be worth checking whether either program applies now, rather than waiting on the patent clock. For everyone else, especially those on the newer, still-protected molecules, the more useful habit is tracking patent challenges and expiration dates directly, since that is the path most likely to bring a lasting price change. Talk with your doctor about what is realistic for your situation, since a prescription will still be required no matter which path eventually lowers your cost.

By Amanda Bonello